Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

Miracles Co-founder and CEO Sabir Hussain always knew he wanted to follow in his father’s footsteps and run his own business. But he never thought that he would launch a biotech company centered around a technology that would be able to help his father after a near-tragic accident that occurred years ago left him bleeding to death.

Bengaluru-based Miraqules has developed nanotechnology in powder form that mimics blood clotting proteins. Rapid coagulation powder produces fibrous compounds at room temperature that have a large volume to ratio and can quickly absorb blood when applied.

“This is a product that will give you instant feedback,” Hussain told TechCrunch. “If someone is bleeding, you put them down, and the bleeding stops. It all happens within a minute or two.”

Miraculz in the top 20 The emerging battlefield The finalists will be presenting this technology on stage in TechCrunch disabled 2025this week in San Francisco.

Hussein said he developed this technology almost by accident.

He went to graduate school for biomedical engineering and began working in a research laboratory focused on biomaterials where his job was essentially mimicking the work of a doctoral student.

“I was really bad at it, actually,” Hussein said. “Its job was to create three-dimensional structures that would help grow bone tissue, which could help form bone. Every time I put this material together, it came apart.”

One day, he took the loose particles and ground them into a powder. He brought this powder to a blood coagulation group that was struggling to mix its solution properly to see if it could help — and it worked.

“It caused the entire blood to clot within five to ten seconds,” Hussein said. “I rushed to my teacher and from there we started thinking about why this happened.” “We have come up with a completely new process of incorporating off-the-shelf materials into a nanomaterial that mimics blood clotting proteins.”

Hussain then teamed up with his childhood friend, Mobeen Medha, and began trying to develop the technology so that it could be taken out of the laboratory, with as little funding as possible.

Since then, the company has been able to obtain 11 patents in seven different countries, including India, the United States, and Israel.

Miraqules’ technology is already being trialled in a trauma care setting in India, and the company expects to receive its regulatory clearance in India within the next few months. It is also on track to receive clearance from the US Food and Drug Administration in 2026.

“One thing we did from the beginning, we went straight to the FDA, there’s something called a pre-submission. We tried to get their feedback on what other necessary things we needed to do to get this product approved, and that helped us a lot.”

The company reached these milestones with less than $700,000 in capital raised, largely from grants.

Miraqules is looking to ramp up deployment and pilot programs in the coming year. It has already received potential interest from 10 different hospital chains in India and the Israel Defense Forces.

If you want to learn from Miraqules first-hand, see dozens of additional offerings, attend valuable workshops, and make connections that drive business results, Head here to learn more about this year’s Disruptheld from October 27 to 29 in San Francisco.